The generic name of Andatang is Dagliflozin, which has a moderate hypoglycemic effect and is suitable for type 2 diabetes mellitus. Dagliflozin is a sodium-glucose cotransporter protein 2 inhibitor, which can inhibit glucose reabsorption, lower the renal glucose threshold, and promote glucose excretion from the urine, so as to achieve the purpose of lowering blood sugar, with moderate hypoglycemic effect. Dagliflozin is suitable for the treatment of type 2 diabetes mellitus on the basis of dietary control and exercise, and is not applicable to patients with type 1 diabetes mellitus and diabetic ketoacidosis. Dagliflozin adverse reactions include genitourinary fungal infections, hypotension, renal impairment, hypoglycemia and so on. This drug is contraindicated in patients who are allergic to dagliflozin, have severe renal impairment, end-stage nephritis, or require dialysis. Precautions for pregnant and lactating women, minors under 18 years of age should be cautious, during the drug should pay attention to monitoring blood pressure, blood sugar, renal function. Dagliflozin should be used in a standardized manner under the guidance of a physician, avoiding self-medication to avoid adverse consequences.